

Docket Number: 037003-0280646
Client Reference: 1992-30-0029CP1C3

Image
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of

ANDERSON et al.

Application No.: 09/911,692

Filed: July 25, 2001



Group Art Unit: 1644

Examiner: Unassigned

Confirmation No.: 8484

For: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES
TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR
TREATMENT OF B CELL LYMPHOMA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached, with the exception of the following documents: (1) items marked with an asterisk are of record in U.S. Application No. 07/978,891, to which the instant application claims priority under 35 U.S.C. § 120; and (2) related international application PCT/US93/10953, published as WO 94/11026, and related U.S. patents, both of which claim priority U.S. Application No. 08/149,099, to which the instant application also claims priority under 35 U.S.C. § 120. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits in the present application. No certification or fee is required.

Respectfully submitted,

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944

Date: March 18, 2004
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/JBM:ntb

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.


M#

Client Ref.

0280646

1992-30-0029CP1C3

INFORMATION DISCLOSURE STATEMENT BY APPLICANT



Applicant: ANDERSON et al.

Appln. No.: 09/911,692

Filing Date: July 25, 2001

Examiner: Schwadron, R. Group Art Unit: 1644

Date: March 18, 2004 Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR 5,595,721	01/1997	KAMINSKI			
	BR 5,439,665	08/1995	HANSEN			
	CR RE 38,008	02/2003	ABRAMS			
	DR 5,736,137	04/1998	ANDERSON			
	ER 5,776,456	07/1998	ANDERSON			
	FR 5,843,439	12/1998	ANDERSON			
	GR 6,399,061	06/2002	ANDERSON			
	HR 6,682,734	01/2004	ANDERSON			

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	IR WO 94/11026	05/1994	PCT	ANDERSON		
	JR					
	KR					
	LR					
	MR					

OTHER

*	NR	Grossbard M.L., et al., "Monoclonal antibody-based therapies of leukemia and lymphoma," <i>Blood</i> , 1992, 80:863-878.				
*	OR	Tedder T.F., et al., "Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes," <i>Eur J Immunol</i> , 1986, 16(8):881-87.				
*	PR	Tedder T.F., et al., "Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19," <i>J Immunol</i> , 1988, 141(12):4388-94.				
	QR					
	RR					
	SR					
	TR					
	UR					

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.